HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Macrophages overexpressing VEGF target to infarcted myocardium and improve neovascularization and cardiac function.

AbstractBACKGROUND:
Clinical trials of vascular endothelial growth factor (VEGF) gene therapy have proven that VEGF has beneficial effects on the ischemic heart disease; however, the lack of a delivery system targeted to the injured myocardium reduces the local therapeutic efficacy of VEGF and increases its possible adverse effects. This study was performed to determine if macrophages transfected with human VEGF165 could incorporate into blood vessels and target to ischemic myocardial tissue to induce neovascularization and improve cardiac function.
METHODS:
Macrophages, macrophages transfected with hVEGF165 or phosphate buffered saline (PBS) were injected intravenously into the mice immediately after coronary artery ligation. Seven days after myocardial infarction (MI), protein expression of VEGF in border zone tissue was quantified by Western blot, and the location of the injected cells was determined by immunofluorescence. Twenty-eight days after MI, capillary density and cardiac function were measured.
RESULTS:
The level of VEGF expression in the mice injected with macrophages overexpressing VEGF was much higher than that in the mice injected with macrophages or PBS (p<0.01for both). Macrophages transfected with hVEGF165 could incorporate into the blood vessels. Furthermore, injection of macrophages overexpressing VEGF significantly augmented capillary density and improved cardiac function.
CONCLUSIONS:
Macrophages transfected with hVEGF165 incorporate into blood vessels and act as a carrier of VEGF that can target ischemic myocardial tissue and contribute to neovascularization and improve cardiac function.
AuthorsDan Yan, Xiaoyan Wang, Dujuan Li, Weishuo Liu, Mincai Li, Zhiling Qu, Qiurong Ruan
JournalInternational journal of cardiology (Int J Cardiol) Vol. 164 Issue 3 Pg. 334-8 (Apr 15 2013) ISSN: 1874-1754 [Electronic] Netherlands
PMID21794934 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Green Fluorescent Proteins
Topics
  • Animals
  • Cell Transplantation (methods)
  • Disease Models, Animal
  • Genetic Therapy (methods)
  • Graft Survival
  • Green Fluorescent Proteins (genetics)
  • Heart (physiology)
  • Hemodynamics (physiology)
  • Macrophages (cytology, transplantation)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Myocardial Infarction (therapy)
  • Neovascularization, Physiologic (physiology)
  • Transfection (methods)
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: